Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Cerilliant
Chinese Patent Office
Harvard Business School
Healthtrust
Medtronic
Johnson and Johnson
Baxter
Farmers Insurance

Generated: May 21, 2018

DrugPatentWatch Database Preview

Neos Theraps Company Profile

« Back to Dashboard

What is the competitive landscape for NEOS THERAPS, and what generic alternatives to NEOS THERAPS drugs are available?

NEOS THERAPS has three approved drugs.

There are six US patents protecting NEOS THERAPS drugs.

There are two patent family members on NEOS THERAPS drugs in two countries.

Summary for Neos Theraps
International Patents:2
US Patents:6
Tradenames:3
Ingredients:2
NDAs:3

Drugs and US Patents for Neos Theraps

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Neos Theraps Inc COTEMPLA XR-ODT methylphenidate TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 205489-001 Jun 19, 2017 RX Yes No 8,840,924 ➤ Try a Free Trial Y ➤ Try a Free Trial
Neos Theraps Inc ADZENYS ER amphetamine SUSPENSION, EXTENDED RELEASE;ORAL 204325-001 Sep 15, 2017 RX Yes Yes 9,265,737 ➤ Try a Free Trial Y ➤ Try a Free Trial
Neos Theraps ADZENYS XR-ODT amphetamine TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 204326-001 Jan 27, 2016 RX Yes No 8,709,491 ➤ Try a Free Trial Y ➤ Try a Free Trial
Neos Theraps ADZENYS XR-ODT amphetamine TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 204326-004 Jan 27, 2016 RX Yes No 9,017,731 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Neos Theraps

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,839,619 Method for treating ADD or ADHD comprising administering amphetamine complexed with ion-exchange resin particles ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Colorcon
UBS
Cipla
US Department of Justice
QuintilesIMS
Dow
Julphar
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.